Clinical Trial

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

Study acronym: HAZEL 401
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 5 locations 2026-06-19
critical Recruitment opened 2026-05-27
Trial Details
NCT Number NCT07438405
Lead Sponsor Amgen
Conditions Thyroid Eye Disease
Enrollment 30 participants
Start Date 2026-05-07
Primary Completion 2028-01-29 (estimated)
Study Completion 2028-07-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-23